Publications

Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KMun, Angeles A, Johnson F et al..  2017.  The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.. Cancer Discov. 7(1):54-71.

Terry S, Beltran H.  2014.  The many faces of neuroendocrine differentiation in prostate cancer progression.. Front Oncol. 4:60.

Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, G Han C, Coleman I et al..  2018.  The long tail of oncogenic drivers in prostate cancer.. Nat Genet. 50(5):645-651.

Ramnarine VRohan, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev M et al..  2018.  The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.. Gigascience.

Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, Montgomery B, Taplin M-E, Pritchard CC, Attard G et al..  2015.  Integrative clinical genomics of advanced prostate cancer.. Cell. 161(5):1215-28.

Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R et al..  2016.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.. N Engl J Med. 375(5):443-53.

Beltran H, Wyatt AW, Chedgy E, Donoghue A, Annala M, Warner E, Beja K, Sigouros M, Mo F, Fazli L et al..  2017.  Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.. Clin Cancer Res.

Beltran H, Park K, Tagawa ST, Yelensky R, Lipson D, Frampton G, Stephens PJ, Cronin MT, Nanus DM, Mosquera JMiguel et al..  2012.  Identifying cancer mutations in neuroendocrine prostate cancer (NEPC) through massively parallel DNA sequencing of formalin-fixed paraffin-embedded (FFPE) tissue.. J Clin Oncol. 30(5_suppl):110.

Demichelis F, Setlur SR, Banerjee S, Chakravarty D, Chen JYun Helen, Chen CX, Huang J, Beltran H, Oldridge DA, Kitabayashi N et al..  2012.  Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.. Proc Natl Acad Sci U S A. 109(17):6686-91.

Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A, Wu R, Brahmbhatt S, Mo F, Jong L et al..  2014.  High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development.. Cancer Res. 74(4):1272-83.

Wilkes DC, Sailer V, Xue H, Cheng H, Collins CC, Gleave M, Wang Y, Demichelis F, Beltran H, Rubin MA et al..  2017.  A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents.. Cold Spring Harb Mol Case Stud. 3(5)

Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH et al..  2012.  From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.. J Pathol. 227(3):286-97.

Beltran H, Kaur G, de España CGarcías, Tagawa ST.  2014.  Exploring the role of anti-angiogenic therapies in prostate cancer: results from the phase 3 trial of sunitinib.. Asian J Androl. 16(4):568-9.

Galletti G, Matov A, Beltran H, Fontugne J, Mosquera JMiguel, Cheung C, MacDonald TY, Sung M, O'Toole S, Kench JG et al..  2014.  ERG induces taxane resistance in castration-resistant prostate cancer.. Nat Commun. 5:5548.

Lin P-C, Chiu Y-L, Banerjee S, Park K, Mosquera JMiguel, Giannopoulou E, Alves P, Tewari AK, Gerstein MB, Beltran H et al..  2013.  Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.. Cancer Res. 73(3):1232-44.

Pauli C, Puca L, Mosquera JMiguel, Robinson BD, Beltran H, Rubin MA, Rao RA.  2016.  An emerging role for cytopathology in precision oncology.. Cancer Cytopathol. 124(3):167-73.

Beltran H.  2013.  DNA mismatch repair in prostate cancer.. J Clin Oncol. 31(14):1782-4.

Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P et al..  2013.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.. Nat Biotechnol. 31(11):1023-31.

Terry S, Maillé P, Baaddi H, Kheuang L, Soyeux P, Nicolaiew N, Ceraline J, Firlej V, Beltran H, Allory Y et al..  2013.  Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer.. Neoplasia. 15(7):761-72.

Terry S, El-Sayed IY, Destouches D, Maillé P, Nicolaiew N, Ploussard G, Semprez F, Pimpie C, Beltran H, Londono-Vallejo A et al..  2015.  CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities.. Oncotarget. 6(14):11994-2008.

Mateo J, Cheng HH, Beltran H, Dolling D, Xu W, Pritchard CC, Mossop H, Rescigno P, Perez-Lopez R, Sailer V et al..  2018.  Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.. Eur Urol.

Beltran H, Tagawa ST, Park K, Macdonald T, Milowsky MI, Mosquera JMiguel, Rubin MA, Nanus DM.  2012.  Challenges in recognizing treatment-related neuroendocrine prostate cancer.. J Clin Oncol. 30(36):e386-9.

Davies AH, Beltran H, Zoubeidi A.  2018.  Cellular plasticity and the neuroendocrine phenotype in prostate cancer.. Nat Rev Urol.

Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KSteve, Talenfeld AD, Nanus DM et al..  2017.  Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.. Cancer.

Rickman DS, Beltran H, Demichelis F, Rubin MA.  2017.  Biology and evolution of poorly differentiated neuroendocrine tumors.. Nat Med. 23(6):1-10.